Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2021

01-03-2021 | Colchicine | Correspondence

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19

Authors: Chia Siang Kow, Syed Shahzad Hasan

Published in: Rheumatology International | Issue 3/2021

Login to get access

Excerpt

The comprehensive review by Misra et al. [1] on the effects of antirheumatic drugs, including hydroxychloroquine, methotrexate and colchicine, in patients with coronavirus disease 2019 (COVID-19), along with discussion on their positive and negative sides to guide repurposing of these antirheumatic drugs against COVID-19, is commendable. Particularly, we read with interest the authors’ viewpoints regarding the potential therapeutic roles of colchicine in patients with COVID-19, and we would like to complement to their discussion on colchicine based on recent understandings on the pathophysiology of COVID-19. …
Literature
1.
Misra DP, Gasparyan AY, Zimba O (2020) Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. RheumatolInt 40(11):1741–1751CrossRef
2.
Busch MH, Timmermans S, Nagy M et al (2020) Neutrophils and contact activation of coagulation as potential drivers of COVID-19. Circulation 142(18):1787–1790CrossRef
3.
Middleton EA, He XY, Denorme F et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136(10):1169–1179CrossRef
4.
Hasan SS, Radford S, Kow CS, Zaidi STR (2020) Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis 50(4):814–821CrossRef
5.
Musoke N, Lo KB, Albano J et al (2020) Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 196:227–230 (published online ahead of print, 2020 Aug 24)CrossRef
6.
Vaidya K, Tucker B, Kurup R, et al. Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients after percutaneous coronary intervention. Preprint. medRxiv. 2020;2020.04.20.20034025
7.
Deftereos SG, Giannopoulos G, Vrachatis DA et al (2020) Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 3(6):e2013136CrossRef
8.
Sandhu T, Tieng A, Chilimuri S, Franchin G (2020) A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol 2020:8865954CrossRef
9.
Lee JJ, Pope JE (2014) A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 16(5):435CrossRef
Metadata
Title
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
Authors
Chia Siang Kow
Syed Shahzad Hasan
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04753-8

Other articles of this Issue 3/2021

Rheumatology International 3/2021 Go to the issue

Observational Research

Topographical analysis of structural lesions between dominant and non-dominant hands in erosive osteoarthritis

Observational Research

Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study

Observational Research

Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands

Case Based Review

Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus

Review

Nurse-led care for the management of rheumatoid arthritis: a review of the global literature and proposed strategies for implementation in Africa and the Middle East

Review

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits